HOME >> MEDICINE >> NEWS
FDA approves Actonel for once-a-week use

Cincinnati, Ohio; Bridgewater, N.J. (May 20, 2002) - The FDA has approved a new 35 mg once-a-week dosage strength for Actonel (risedronate sodium tablets) for the prevention and treatment of postmenopausal osteoporosis. This approval offers patients the convenience of a once-a-week dosing option to manage their osteoporosis and protect their bones. It will be available in mid-June 2002, by prescription only.

Actonel 35 mg once-a-week is a valuable new tool for the treatment and prevention of postmenopausal osteoporosis, said Robert Lindsay, M.D., Ph.D., Chief of Internal Medicine at Helen Hayes Hospital, Professor of Clinical Medicine, Columbia University, and principal investigator of the Actonel once-a-week approval study. Patients and doctors always welcome effective new treatment choices, and we now have data that show once-a-week dosing of Actonel is therapeutically equivalent to daily 5 mg dosing."

The FDA based its approval on safety and efficacy data from a one-year, double-blind, multicenter study that included 1,456 postmenopausal women with osteoporosis and compared the effects of the once-a-week and daily dosing of Actonel on bone mineral density (BMD). Patients taking Actonel 35 mg once-a-week experienced a significant increase in lumbar spine BMD at 12 months versus baseline -- an increase that was similar to that achieved with the Actonel 5 mg daily dose. There was also a significant increase in BMD versus baseline at the hip at 12 months, an increase that was similar in both treatment groups.

The overall safety and tolerability profiles of Actonel 35 mg once-a-week and 5 mg daily were similar in the study. Consistent with other pivotal Actonel clinical studies, patients were not excluded based on a history of, or active, GI disease.


'"/>

Contact: Ashley Donnelly
adonnelly@hillandknowlton.com
212-885-0488
Hill and Knowlton
20-May-2002


Page: 1

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves EPZICOM
6. FDA approves new labelling for Seroquel in bioplar mania
7. FDA approves Enbrel to treat psoriasis
8. FDA approves Climara Pro to treat menopause symptoms
9. FDA approves new approach to schizophrenia treatment
10. FDA approves new HIV protease inhibitor, Lexiva (TM)
11. FDA approves Wellbutrin XL(TM)

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... 31, 2020 , ... Genesis Chiropractic Software and Billing ... launch of its integrated, HIPAA compliant, telehealth solution, available to US-based clients immediately. ... 90 seconds. , According to the U.S. Department of Health & Human ...
(Date:8/31/2020)... ... ... Covid-19 “PTS” with Mediation & Hypnosis , At this very turbulent time in the ... anxiety, immense stress, and right now are needing serious relief from a constant state of ... are experiencing a great degree of emotional discomfort, be it fear or worrying about their ...
(Date:8/29/2020)... (PRWEB) , ... August 29, 2020 , ... When professor ... perhaps with greater ease than most people would. Rather than become melancholic, however, he ... deep advice on achieving one’s dreams. Randy Pausch took a negative situation and turned ...
(Date:8/28/2020)... ... August 28, 2020 , ... With in-person ... out to continue helping the specialty-diet community connect with great, gluten-free brands. At ... coupons, enter giveaways, chat with brands & watch over 50 educational classes... all ...
(Date:8/27/2020)... ... August 27, 2020 , ... ... Walk-in Dermatology team in its Greenvale, New York location. , Loren received ... Care Institute. She is certified in chemical peels, microdermabrasion, Hydrafacial MD, dermaplaning, facial ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... CHAPEL HILL, N.C. (PRWEB) , ... August 27, 2020 , ... ... Jensen, professional football player and sleep apnea patient, is the company’s new spokesperson. , ... on the football field. So, when I found the Bleep DreamPort it was a ...
(Date:8/27/2020)... ... August 27, 2020 , ... The GHT Companies , a leading developer ... Feeding San Diego with a press conference at its manufacturing facility in ... check of $5,000.00+ representing an overall donation result exceeding $30,000 to Feeding San Diego, ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... Testing division, expands its technology footprint with the addition of Novocyte Quanteon™ ... With industry-leading biomarker solutions, complemented with traditional ligand-binding assays and study management ...
Breaking Medicine Technology:
Cached News: